Physician profile
Wei Cheng
NPI 1699938142
$2,744.70
in general payments reported to CMS, 2019-2025
32 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,685 · 2020: $232 · 2021: $126 · 2022: $35.30 · 2023: $209 · 2024: $258 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $681.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $386.47 | 2019-2020 | |
| Astellas Pharma US INC | $318.12 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $162.73 | 2019 | |
| Lilly USA, LLC | $108.07 | 2019-2025 | Mounjaro, Zepbound |
| Horizon Therapeutics Plc | $102.61 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.46 | 2019 | |
| Abbvie INC. | $94.21 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.01 | 2019 | |
| Abbott Laboratories | $69.63 | 2023-2025 | Freestyle Libre |
| E.R. Squibb & Sons, L.L.C. | $63.17 | 2024 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $62.95 | 2019 | |
| Allergan, INC. | $52.40 | 2019 | |
| Glaxosmithkline, LLC. | $50.37 | 2019-2021 | |
| Genentech USA, INC. | $48.74 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $42.34 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $35.30 | 2022 | |
| Amgen INC. | $34.91 | 2020-2021 | |
| Eisai INC. | $23.34 | 2019 | |
| Pharming Healthcare, INC. | $22.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.74 | 2025 | |
| Pfizer INC. | $20.06 | 2025 | |
| Zyla Life Sciences, INC. | $19.36 | 2019 | |
| Csl Behring | $18.42 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.71 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.50 | 2024 | |
| Exact Sciences Corporation | $16.52 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $15.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.26 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.81 | 2019 | |
| Phadia US INC. | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.